Skip to Content
Learn about Adcetris a treatment of Hodgkin Lymphoma

Pentostatin Pregnancy and Breastfeeding Warnings

Pentostatin is also known as: Nipent

Medically reviewed on Aug 6, 2018

Pentostatin Pregnancy Warnings

Pentostatin has been assigned to pregnancy category D by the FDA. It may cause fetal harm when administered to pregnant women. Animal studies have revealed evidence of teratogenicity. There are no controlled data in human pregnancy. If this drug is used during pregnancy, or if the patient becomes pregnant while receiving this drug, the patient should be apprised of the potential hazard to the fetus. Women of childbearing potential should be advised to avoid becoming pregnant during therapy.

See references

Pentostatin Breastfeeding Warnings

There are no data on the excretion of pentostatin into human milk. Because many drugs are excreted in human milk, and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the nursing mother.

See references

References for pregnancy information

  1. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.

References for breastfeeding information

  1. "Product Information. Nipent (pentostatin)." Parke-Davis, Morris Plains, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.